Search Results

There are 7598 results for: content related to: Pioglitazone and vitamin E for nonalcoholic steatohepatitis: A cost utility analysis

  1. You have free access to this content
    Do thiazolidinediones still have a role in treatment of type 2 diabetes mellitus?

    Diabetes, Obesity and Metabolism

    Volume 15, Issue 11, November 2013, Pages: 967–977, A. Consoli and G. Formoso

    Version of Record online : 18 APR 2013, DOI: 10.1111/dom.12101

  2. Pioglitazone for type 2 diabetes mellitus

    Intervention Review

    The Cochrane Library

    Bernd Richter, Elizabeth Bandeira-Echtler, Karla Bergerhoff, Christine Clar and Susanne H Ebrahim

    Published Online : 18 OCT 2006, DOI: 10.1002/14651858.CD006060.pub2

  3. You have free access to this content
    Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis

    British Journal of Clinical Pharmacology

    Volume 78, Issue 2, August 2014, Pages: 258–273, Richard M. Turner, Chun S. Kwok, Chen Chen-Turner, Chinedu A. Maduakor, Sonal Singh and Yoon K. Loke

    Version of Record online : 21 JUL 2014, DOI: 10.1111/bcp.12306

  4. Earlier triple therapy with pioglitazone in patients with type 2 diabetes

    Diabetes, Obesity and Metabolism

    Volume 11, Issue 9, September 2009, Pages: 844–854, G. Charpentier, S. Halimi and on behalf of the F-PIO-100 Study Investigators

    Version of Record online : 13 JUL 2009, DOI: 10.1111/j.1463-1326.2009.01055.x

  5. Residual effect of reductions in red blood cell count and haematocrit and haemoglobin levels after 10-month withdrawal of pioglitazone in patients with Type 2 diabetes

    Diabetic Medicine

    Volume 31, Issue 11, November 2014, Pages: 1341–1349, K.-D. Lin, M.-Y. Lee, C.-C. Feng, B. K. Chen, M.-L. Yu and S.-J. Shin

    Version of Record online : 30 MAY 2014, DOI: 10.1111/dme.12481

  6. Observational follow-up of the PROactive study: a 6-year update

    Diabetes, Obesity and Metabolism

    Volume 16, Issue 1, January 2014, Pages: 63–74, E. Erdmann, E. Song, R. Spanheimer, A.-R. van Troostenburg de Bruyn and A. Perez

    Version of Record online : 19 AUG 2013, DOI: 10.1111/dom.12180

  7. The role of pioglitazone in modifying the atherogenic lipoprotein profile

    Diabetes, Obesity and Metabolism

    Volume 11, Issue 8, August 2009, Pages: 742–756, M. Hanefeld

    Version of Record online : 10 JUN 2009, DOI: 10.1111/j.1463-1326.2009.01048.x

  8. Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes

    Diabetes, Obesity and Metabolism

    Volume 14, Issue 5, May 2012, Pages: 409–418, J. Wainstein, L. Katz, S. S. Engel, L. Xu, G. T. Golm, S. Hussain, E. A. O’Neill, K. D. Kaufman and B. J. Goldstein

    Version of Record online : 22 DEC 2011, DOI: 10.1111/j.1463-1326.2011.01530.x

  9. Pioglitazone has a dubious bladder cancer risk but an undoubted cardiovascular benefit

    Diabetic Medicine

    Volume 32, Issue 3, March 2015, Pages: 305–313, R. E. J. Ryder

    Version of Record online : 3 DEC 2014, DOI: 10.1111/dme.12627

  10. Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials

    Diabetes, Obesity and Metabolism

    Volume 10, Issue 12, December 2008, Pages: 1221–1238, E. Mannucci, M. Monami, C. Lamanna, G. F. Gensini and N. Marchionni

    Version of Record online : 26 MAY 2008, DOI: 10.1111/j.1463-1326.2008.00892.x

  11. Efficacy and safety of initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes: a 54-week study

    Diabetes, Obesity and Metabolism

    Volume 14, Issue 8, August 2012, Pages: 745–752, K. H. Yoon, H. Steinberg, R. Teng, G. T. Golm, M. Lee, E. A. O'Neill, K. D. Kaufman and B. J. Goldstein

    Version of Record online : 17 APR 2012, DOI: 10.1111/j.1463-1326.2012.01594.x

  12. Sitagliptin and pioglitazone provide complementary effects on postprandial glucose and pancreatic islet cell function

    Diabetes, Obesity and Metabolism

    Volume 15, Issue 12, December 2013, Pages: 1101–1110, M. Alba, B. Ahrén, S. E. Inzucchi, Y. Guan, M. Mallick, L. Xu, E. A. O'Neill, D. E. Williams-Herman, K. D. Kaufman and B. J. Goldstein

    Version of Record online : 18 JUL 2013, DOI: 10.1111/dom.12145

  13. Beneficial effects of pioglitazone against cardiovascular injury are enhanced by combination with aliskiren in a rat model of diabetic nephropathy

    Journal of Pharmacy and Pharmacology

    Volume 64, Issue 6, June 2012, Pages: 862–871, Rania A. Elrashidy, Mervat E. Asker and Hoda E. Mohamed

    Version of Record online : 29 MAR 2012, DOI: 10.1111/j.2042-7158.2012.01508.x

  14. Effect of pioglitazone in combination with insulin therapy on glycaemic control, insulin dose requirement and lipid profile in patients with type 2 diabetes previously poorly controlled with combination therapy

    Diabetes, Obesity and Metabolism

    Volume 9, Issue 4, July 2007, Pages: 512–520, P. Berhanu, A. Perez and S. Yu

    Version of Record online : 4 AUG 2006, DOI: 10.1111/j.1463-1326.2006.00633.x

  15. Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study

    Diabetes, Obesity and Metabolism

    Volume 10, Issue 1, January 2008, Pages: 82–90, G. Bolli, F. Dotta, E. Rochotte and S. E. Cohen

    Version of Record online : 22 NOV 2007, DOI: 10.1111/j.1463-1326.2007.00820.x

  16. Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study

    Diabetes, Obesity and Metabolism

    Volume 13, Issue 11, November 2011, Pages: 1028–1035, K. Kaku, T. Itayasu, S. Hiroi, M. Hirayama and Y. Seino

    Version of Record online : 28 SEP 2011, DOI: 10.1111/j.1463-1326.2011.01460.x

  17. Proteinuria testing among patients with diabetes mellitus is associated with bladder cancer diagnosis: potential for unmeasured confounding in studies of pioglitazone and bladder cancer

    Pharmacoepidemiology and Drug Safety

    Volume 23, Issue 6, June 2014, Pages: 636–645, James D. Lewis, Laurel Habel, Charles Quesenberry, Ronac Mamtani, Tiffany Peng, Warren B. Bilker, Monique Hedderson, Lisa Nessel, David J. Vaughn, Brian L. Strom and Assiamira Ferrara

    Version of Record online : 25 APR 2014, DOI: 10.1002/pds.3619

  18. Effects of pioglitazone on lipid and lipoprotein metabolism

    Diabetes, Obesity and Metabolism

    Volume 9, Issue 5, September 2007, Pages: 640–647, D. John Betteridge

    Version of Record online : 26 FEB 2007, DOI: 10.1111/j.1463-1326.2007.00715.x

  19. PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK

    Diabetic Medicine

    Volume 24, Issue 9, September 2007, Pages: 982–1002, W. J. Valentine, J. M. Bottomley, A. J. Palmer, M. Brändle, V. Foos, R. Williams, J. A. Dormandy, J. Yates, M. H. Tan, M. Massi-Benedetti and on behalf of the PROactive Study Group

    Version of Record online : 25 JUN 2007, DOI: 10.1111/j.1464-5491.2007.02188.x

  20. You have free access to this content
    Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes

    Diabetes, Obesity and Metabolism

    Volume 9, Issue 2, March 2007, Pages: 175–185, J. Rosenstock, S. W Kim, M. A. Baron, R.-P. Camisasca, F. Cressier, A. Couturier and S. Dejager

    Version of Record online : 31 JAN 2007, DOI: 10.1111/j.1463-1326.2006.00698.x